Dasatinib: ten years of clinical practice worldwide
The article contains results of meta-analysis of experience in use of second-generation tyrosine kinase inhibitors – dasatinib. The results of clinical trials dasatinib therapy in chronic myelogenous leukemia imatinib-resistant or intolerant patients are presented. The dasatinib and imatinib compara...
Saved in:
| Main Authors: | K. M. Abdulkadyrov, V. A. Shuvaev, I. S. Martynkevich |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2016-03-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/178 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
by: Zhen-Yu Xiong, et al.
Published: (2024-12-01) -
Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01) -
Current and future of targeted therapies against BCR::ABL kinases
by: Sridhar Jayavel, et al.
Published: (2025-04-01) -
Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01) -
The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
by: Xiaoxia Wu, et al.
Published: (2024-09-01)